Int. J. Biol. Sci. 2021, Vol. 17 2080 Ivyspring International Publisher International Journal of Biological Sciences 2021; 17(8): 2080-2088. doi: 10.7150/ijbs.60655 Review COVID-19 one year later: a retrospect of CRISPR-Cas system in combating COVID-19 Yan Zhan1,2,3, Xiang-Ping Li5 and Ji-Ye Yin1,2,3,4 1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, P. R. China; Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P. R. China. 2. Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha 410078, P. R. China. 3. National Clinical Research Center for Geriatric Disorders, 87 Xiangya Road, Changsha 410008, Hunan, P.R. China. 4. Hunan Key Laboratory of Precise Diagnosis and Treatment of Gastrointestinal Tumor, Changsha 410078, P. R. China. 5. Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, P. R. China. Corresponding authors: Professor Ji-Ye Yin, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008; P. R. China. Tel: +86 731 84805380, Fax: +86 731 82354476, E-mail:
[email protected]. ORCID: 0000-0002-1244-5045; Professor Xiang-Ping Li, Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, P. R. China. Tel: +86 731 84327453. Fax: +86 731 84327453, E‐mail:
[email protected]. ORCID: 0000-0002-5801-489X. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.